Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Idalopirdine in Hepatic Impairment
NCT02231450Phase 1Completed
- Sponsor
- Lundbeck
- Start
- Jul 2014
- Primary completion
- Mar 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of Idalopirdine in Alzheimer's disease (AD) (3 arms), sponsored by Lundbeck. Primary endpoints: Area under the plasma concentration-time curve from time zero to infinity and Maximum observed plasma concentration. Started Jul 2014; status: completed.
02
Drugs
Idalopirdine
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT02231450.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02231450.